Roxane Laboratories Announces The Launch Of Sertraline Hydrochloride Tablets, 25mg, 50mg, 100mg

COLUMBUS, Ohio, Feb. 7 /PRNewswire/ -- Roxane Laboratories, Inc. today announced the launch of Sertraline Hydrochloride Tablets, 25mg, 50mg, 100mg. The product will be available in bottles of 30 and 480.

Roxane Laboratories' Sertraline Hydrochloride Tablets, 25mg, 50mg, 100mg are AB rated to ZOLOFT(R) (sertraline hydrochloride) Tablets, 25mg, 50mg, 100mg. Sertraline Hydrochloride Tablets had total annual sales of approximately $3.07 Billion, based on IMS sales data for the twelve months ending September 2006.

Roxane Laboratories

Roxane Laboratories, Inc. (Columbus, Ohio), is a subsidiary of Boehringer Ingelheim Corporation, based in Ridgefield, CT and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 143 affiliates in 47 countries and approximately 37,500 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2005, Boehringer Ingelheim posted net sales of US $11.8 billion (9.5 billion euro) while spending approximately one-fifth of net sales in its largest business segment, Prescription Medicines, on research and development.

For more information, please visit

Full prescribing information for Sertraline Hydrochloride Tablets, 25mg, 50mg, 100mg is available on the Roxane web site at or upon request by calling Roxane Laboratories Technical Product Information at 1-800- 962-8364.

(1) IMS MAT dollar sales ending September 2006

ZOLOFT(R) is a registered trademark of Pfizer Pharmaceuticals.

Roxane Laboratories, Inc.

CONTACT: Jason Kurtz, Communications & Public Relations, for RoxaneLaboratories, Inc., +1-440-201-3668, or Fax, +1-440-232-8751,

Back to news